A narrative review summarizes evidence for ctDNA minimal residual disease testing in gastrointestinal cancers, with strongest data supporting use in resected stage II colon cancer. (Clinical and Translational Oncology)
Practical guidance for integrating ctDNA testing into clinical care
The CRC Digest